HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT00071253

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Medication studyAges 18–65United StatesBipolarity
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
Anaheim and 14 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJuly 2003
Recruitment status
Terminated
Enrollment listed in the registry
180
Sponsor
Abbott
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00071253
Official title
Show the full official title

A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Recruitment & locations

Terminated

Anaheim · Chula Vista · Fort Meyers

12 more locations
  • North Miami
  • Chicago
  • Louisville
  • Jackson
  • Omaha
  • North Las Vegas
  • New York
  • Cleveland
  • Lyndhurst
  • Oklahoma City
  • Galveston
  • Milwaukee

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Abbott.

Does this study involve medication?

Yes. The study involves medication, including Divalproex Sodium (Delayed-Release Tablets), Divalproex Sodium (Extended-Release Tablets) and Olanzapine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies